One Health in Regenerative Medicine: Report on the Second Havemeyer Symposium on Regenerative Medicine in Horses

Fortier, Lisa A.; Goodrich, Laurie R.; Ribitsch, Iris; Schnabel, Lauren V.; Shepard, David Owen; Walle, Gerlinde R. Van de; Watts, Ashlee E.; Smith, R. K. W.

doi:10.2217/rme-2019-0143

Cited by 5 publications

(3 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This increased use may be attributed to increased commercial availability and advertisement of biologic products coupled with extensive literature surrounding the use of biologic therapies for musculoskeletal disease. 20 Platelet-rich plasma was the most widely used biologic therapy by large animal diplomates. Despite the differences in survey populations, our study and Velloso et al (2020) indicated that PRP was the most widely used biologic therapy for musculoskeletal disease.…”

Section: Discussionmentioning

confidence: 99%

“…Our study suggested a similar level of use amongst large animal specialists, irrespective of their duration in practice or practice type. This increased use may be attributed to increased commercial availability and advertisement of biologic products coupled with extensive literature surrounding the use of biologic therapies for musculoskeletal disease 20 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Current use of biologic therapies for musculoskeletal disease: A survey of board‐certified equine specialists

et al. 2022

View full text Add to dashboard Cite

Objective To evaluate the use of mesenchymal stem cells (MSCs), autologous conditioned serum (ACS), platelet‐rich plasma (PRP), and autologous protein solution (APS) for the treatment of equine musculoskeletal disease by diplomates of the American College of Veterinary Surgery (ACVS), and American College of Veterinary Sports Medicine and Rehabilitation (ACVSMR). Study design Cross‐sectional study. Sample population Diplomates (n = 423). Methods An email link was sent to ACVS and ACVMR diplomates. A survey contained 59 questions regarding demographics, as well as indications, frequency, adverse effects, and limitations of use. Responses were analyzed using Fisher's exact test. Results One hundred and fifty four surveys were analyzed. Years in practice and type of practice were not associated with biologic therapy use. PRP was the most used therapy (120/137; 87.5%). PRP and MSCs were most often administered intralesionally while ACS and APS were most often administered intra‐articularly. ACS (50/104; 48.1%) treatment was repeated commonly within 2 weeks of initial injection. MSCs (39/90; 43.3%) and PRP (38/100; 38%) were commonly repeated 1‐2 months after initial injection and APS was typically repeated >4 months after initial injection (21/53; 39.6%). Local inflammation and expense were the most common adverse effect and limitation of use. Conclusion Diplomates most commonly utilized PRP and MSC intralesionally for soft‐tissue injuries, and ACS and ACP intra‐articularly for joint injury. Protocols for repeated administration varied widely. Local inflammation was a clinical concern with the use of biologics. Clinical significance Biologic therapies are used commonly by ACVS and ACVSMR diplomates for soft tissue and joint disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Current use of biologic therapies for musculoskeletal disease: A survey of board‐certified equine specialists

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Mesenchymal stem/stromal cells (MSCs) are adult multipotent stem cells that have attracted significant interest for regenerative medicine due to their distinct biological properties ( 1 , 2 ). Since the underlying causes of certain diseases are similar in both people and animals, the findings obtained from MSC research can be valuable for both human and veterinary patients, promoting the concept of “One Health, One Medicine” ( 3 , 4 ). Horses are of particular importance in translational medicine, as they suffer from various pathologies analogous to human with inflammatory and immune components, in which the ability of MSCs to modulate the immune system through their paracrine activity has broadened the scope of potential applications ( 5 ).…”

Section: Introductionmentioning

confidence: 99%

The systemic cellular immune response against allogeneic mesenchymal stem cells is influenced by inflammation, differentiation and MHC compatibility: in vivo study in the horse

Cequier,

Vázquez,

Vitoria

et al. 2024

Front. Vet. Sci.

View full text Add to dashboard Cite

The effectiveness and safety of allogeneic mesenchymal stem/stromal cells (MSCs) can be affected by patient’s immune recognition. Thus, MSC immunogenicity and their immunomodulatory properties are crucial aspects for therapy. Immune responses after allogeneic MSC administration have been reported in different species, including equine. Interactions of allogenic MSCs with the recipient’s immune system can be influenced by factors like matching or mismatching for the major histocompatibility complex (MHC) between donor-recipient, and by the levels of MHC expression in MSCs. The latter can vary upon MSC inflammatory exposure or differentiation, such as chondrogenic induction, making both priming and differentiation interesting therapeutic strategies. This study investigated the systemic in vivo immune cellular response against allogeneic equine MSCs in these situations. Either MSCs in basal conditions (MSC-naïve), pro-inflammatory primed (MSC-primed) or chondrogenically differentiated (MSC-chondro) were repeatedly administered subcutaneously into autologous, MHC-matched or MHC-mismatched allogeneic equine recipients. At different time-points after each administration, lymphocytes were obtained from recipient horses and exposed in vitro to the same type of MSCs to assess the proliferative response of different T cell subsets (cytotoxic, helper, regulatory), B cells, and interferon gamma (IFNγ) secretion. Higher proliferative response of helper and cytotoxic T lymphocytes and IFNγ secretion was observed in response to all types of MHC-mismatched MSCs over MHC-matched ones. MSC-primed produced the highest immune response, followed by MSC-naïve, and MSC-chondro. However, MSC-primed activated Treg and had a mild effect on B cells, and the response after their second administration was similar to the first one. On the other hand, both MSC-chondro and MSC-naïve barely induced Treg response but promoted B lymphocyte activation, and proportionally induced a higher cell response after the second administration. In conclusion, both the type of MSC conditioning and the MHC compatibility influenced systemic immune recognition of equine MSCs after single and repeated administrations, but the response was different. Selecting MHC-matched donors would be particularly recommended for MSC-primed and repeated MSC-naïve administrations. While MHC-mismatching in MSC-chondro would be less critical, B cell response should not be ignored. Comprehensively investigating the in vivo immune response against equine allogeneic MSCs is crucial for advancing veterinary cell therapies.

show abstract

Appendix 1

2023

One Health Meets the Exposome

View full text Add to dashboard Cite

One Health in Regenerative Medicine: Report on the Second Havemeyer Symposium on Regenerative Medicine in Horses

Cited by 5 publications

References 76 publications

Current use of biologic therapies for musculoskeletal disease: A survey of board‐certified equine specialists

Current use of biologic therapies for musculoskeletal disease: A survey of board‐certified equine specialists

The systemic cellular immune response against allogeneic mesenchymal stem cells is influenced by inflammation, differentiation and MHC compatibility: in vivo study in the horse

Appendix 1

Contact Info

Product

Resources

About